Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Deferoxamine mesylate
Related Products

Hot Products

Basic Information Post buying leads Suppliers Cas Database
Name

Deferoxamine mesylate

 EINECS 205-314-3
CAS No. 138-14-7 Density N/A
PSA 268.59000 LogP 2.98900
Solubility N/A Melting Point 148-149°
Formula C25H48N6O8.CH4O3S Boiling Point 966.9 °C at 760 mmHg
Molecular Weight 656.798 Flash Point 538.5 °C
Transport Information N/A Appearance white to off-white powder
Safety 22-24/25 Risk Codes N/A
Molecular Structure Molecular Structure of 138-14-7 (Deferoxamine mesylate) Hazard Symbols N/A
Synonyms

Deferoxamine mesilate (JP14);Desferal;Prestwick_988;Deferoxamine mesylate (USP);Butanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino) pentyl]amino]-1,4-dioxobutyl]hydroxyamino] pentyl]-N-(5-aminopentyl)-Nhydroxy-,monomethanesulfonate (salt);Desferal (TN);

Article Data 1

Deferoxamine mesylate Synthetic route

138-14-7

deferoxamine mesylate

89Zr(Ox)2

89Zr(Ox)2

C25H45N6O8(89)Zr

Conditions
ConditionsYield
With sodium carbonate In water at 24℃; for 0.25h; pH=7 - 7.5;100%
108-30-5

succinic acid anhydride

138-14-7

deferoxamine mesylate

84211-47-2

N-Succinyl-desferri-ferrioxyamin B

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 42h; Inert atmosphere;97%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 50℃; Solvent; Temperature; Inert atmosphere;
With pyridine at 20℃; Inert atmosphere;0.232 g
4349-62-6

2-benzyloxybenzoyl chloride

138-14-7

deferoxamine mesylate

101536-58-7

N,O',O'',O'''-Tetra(2-benzyloxy-benzoyl)desferri-ferrioxamin B

Conditions
ConditionsYield
With sodium hydrogencarbonate In diethyl ether; water for 1h;93%
138-14-7

deferoxamine mesylate

35013-72-0

biotin N-Hydroxysuccinimide ester

1150314-06-9

DFOB-AdA

Conditions
ConditionsYield
With sodium hydroxide In methanol at 40℃; for 4h; Product distribution / selectivity;92%
28320-76-5

1-(N-succinimidyloxycarbonyl)adamantane

138-14-7

deferoxamine mesylate

1150314-06-9

DFOB-AdA

Conditions
ConditionsYield
Stage #1: deferoxamine mesylate With sodium hydroxide In methanol
Stage #2: 1-(N-succinimidyloxycarbonyl)adamantane In methanol at 55℃; for 4h; Product distribution / selectivity;		92%
4044-65-9

1 ,4-phenylenediisothiocyanate

138-14-7

deferoxamine mesylate

1222468-90-7

N-[5-({3-[5-(acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-hydroxy-N'-{5-[3-(4-isothiocyanato-phenyl)-thioureido]-pentyl}-succinamide

Conditions
ConditionsYield
With triethylamine In chloroform; water; isopropyl alcohol85%
24424-99-5

di-tert-butyl dicarbonate

138-14-7

deferoxamine mesylate

106339-54-2

1-(tert-Butoxycarbonyl)-7,18,29-trihydroxy-8,11,19,22,30-pentaoxo-1,7,12,18,23,29-hexaazahentriacontane

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water at 40℃; for 16h;83%
With sodium carbonate In 1,4-dioxane; water
138-14-7

deferoxamine mesylate

5231-87-8

3,4-diethoxy-3-cyclobuten-1,2-dione

C31H52N6O11

Conditions
ConditionsYield
Stage #1: deferoxamine mesylate With N-ethyl-N,N-diisopropylamine In ethanol at 50℃; for 1h;
Stage #2: 3,4-diethoxy-3-cyclobuten-1,2-dione In ethanol at 50℃; for 0.5h;		83%
Stage #1: deferoxamine mesylate With N-ethyl-N,N-diisopropylamine In ethanol at 50℃; for 1h;
Stage #2: 3,4-diethoxy-3-cyclobuten-1,2-dione In ethanol at 50℃; for 0.5h;		83%

C19H22N2O9

138-14-7

deferoxamine mesylate

C41H67N7O14

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide for 4h;82%
14670-94-1

3,5-dimethyl-1-adamantanecarboxylic acid

138-14-7

deferoxamine mesylate

1149568-52-4

DFOB-AdAdMe

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; Inert atmosphere;80%

Deferoxamine mesylate Chemical Properties

Molecular Structure of Deferoxamine mesylate (CAS NO.138-14-7):

IUPAC Name: N-[5-[[4-[5-[Acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide ; Methanesulfonic acid
Molecular Weight: 656.78968 [g/mol]
Molecular Formula: C26H52N6O11S
H-Bond Donor: 7
H-Bond Acceptor: 12 
EINECS: 205-314-3 
Storage temp.: −20 °C
Solubility: H2O: 50 mg/mL
Appearance: white to off-white  powder
Flash Point: 538.5 °C
Enthalpy of Vaporization: 152.67 kJ/mol
Boiling Point: 966.9 °C at 760 mmHg
Vapour Pressure: 0 mmHg at 25 °C
Classification Code: Antidote [to iron poisoning]; Chelating agent; Drug / Therapeutic Agent; Human Data

Deferoxamine mesylate Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo parenteral 16gm/kg/34W-I (16000mg/kg) CARDIAC: PERICARDITIS

GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE

BLOOD: OTHER CHANGES		 American Journal of Kidney Diseases. Vol. 10, Pg. 71, 1987.
man TDLo subcutaneous 143mg/kg/4D-I (143mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

GASTROINTESTINAL: NAUSEA OR VOMITING		 British Medical Journal. Vol. 291, Pg. 448, 1985.
mouse LD50 intraperitoneal 1240mg/kg (1240mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 1181, 1973.
mouse LD50 intravenous 273mg/kg (273mg/kg)   Drugs in Japan Vol. 6, Pg. 496, 1982.
mouse LD50 oral 15200mg/kg (15200mg/kg)   Drugs in Japan Vol. 6, Pg. 496, 1982.
mouse LD50 subcutaneous 1280mg/kg (1280mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA		 Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 1181, 1973.
rat LD50 intravenous 330mg/kg (330mg/kg)   Drugs in Japan Vol. 6, Pg. 496, 1982.
rat LD50 oral 17300mg/kg (17300mg/kg)   Drugs in Japan Vol. 6, Pg. 496, 1982.
rat LD50 subcutaneous 5500mg/kg (5500mg/kg)   Drugs in Japan Vol. 6, Pg. 496, 1982.
women TDLo subcutaneous 150mg/kg/4D-I (150mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

GASTROINTESTINAL: NAUSEA OR VOMITING		 British Medical Journal. Vol. 291, Pg. 448, 1985.
women TDLo unreported 900mg/kg/30W- (900mg/kg) BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES

CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA		 American Journal of Medicine. Vol. 87, Pg. 468, 1989.

Deferoxamine mesylate Safety Profile

Safety Information of Deferoxamine mesylate (CAS NO.138-14-7):
Safety Statements: 22-24/25
 S22:Do not breathe dust. 
S24/25:Avoid contact with skin and eyes.
WGK Germany: 2
RTECS: UG5310000
Poison by intravenous route. Moderately toxic by subcutaneous and intraperitoneal routes. Mildly toxic by ingestion. Human systemic effects: acute pulmonary edema, blood changes, cardiomyopathy, degenerative brain changes, diarrhea, hypermotility, nausea or vomiting, pericarditis, ulceration or bleeding from small intestine, visual field changes. When heated to decomposition it emits toxic fumes of NOx and SOx.

Deferoxamine mesylate Specification

 Deferoxamine mesylate (CAS NO.138-14-7), its Synonyms are Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate ; Desferal methanesulfonate ; Desferrioxamine B mesylate ; Desferrioxamine B methanesulfonate ; Desferrioxamine mesylate ; Desferrioxamine methanesulfonate ; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid monomethanesulfonate (salt) .

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 138-14-7